Memorial Sloan Kettering Cancer Center: Thyroid Neoplasms trials

The registry lists 24 Thyroid Neoplasms studies with Memorial Sloan Kettering Cancer Center as lead sponsor. 5 are open to participants now and 5 have results posted.

Early Phase 1 2Phase 1 5Phase 2 7No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Meaning-Centered Therapy for Mexican Adults With Advanced CancerRecruitingNCT07225309Not applicable
• A Study of Avutometinib and Defactinib in People With Thyroid CancerRecruitingNCT06007924Phase 2
• A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid CancerRecruitingNCT05733013
• Lesion Dosimetry With Iodine-124 in Metastatic Thyroid CarcinomaRecruitingNCT03647358Phase 1
• New MRI Biomarkers in Head and Neck CancersRecruitingNCT03483337
• Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid CancersCompletedNCT04462471Phase 1Results posted
• RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid CancersActive, not recruitingNCT03215095Early Phase 1Results posted
• Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid CancerCompletedNCT01882816Phase 2Results posted
• Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid CancerCompletedNCT01025453Phase 2Results posted
• Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244CompletedNCT00970359Not applicableResults posted
• Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid CancerWithdrawnNCT04868045Phase 1
• Laser Ablation of Papillary Thyroid MicrocarcinomaActive, not recruitingNCT04623801Phase 2
• PDR001 Combination Therapy for Radioiodine-Refractory Thyroid CancerActive, not recruitingNCT04544111Phase 2
• Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid CancerActive, not recruitingNCT04238624Phase 2
• A Study of Optical Imaging With Light From Radiotracers in Cancer PatientsActive, not recruitingNCT03484884
• Decision Making and Psychological Outcomes in Low-Risk Papillary Thyroid CancerCompletedNCT03300284
• Study of PET Imaging With 18F-TFB in Patients With Thyroid CancerActive, not recruitingNCT03196518Not applicable
• Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid CancerCompletedNCT03122496Phase 1
• Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid CancerCompletedNCT02178345
• Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot StudyCompletedNCT02145143Early Phase 1
• Measuring Patient Expectations for Thyroid SurgeryActive, not recruitingNCT01412762
• Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant OthersCompletedNCT01392222
• Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid CancerActive, not recruitingNCT01141309Phase 2
• Lesion Dosimetry With 124-Iodine in Metastatic Thyroid CarcinomaCompletedNCT00673010Phase 1